Chimerix, Inc.
Durham, United States
- Dr. Prabhu has over a decade of experience in the field of oncology drug development in industry and academia and is committed to translating findings at the bench to improve cancer therapy for patients.
- He worked on investigational agent ONC201 currently in clinical development for H3K27M glioma starting from early preclinical efficacy and target validation studies through Phase I/II/III.
- He is a co-inventor of the small molecule imipridone scaffold for therapeutic targeting of GPCRs, and lead the clinical introduction of second-generation agent ONC206 from hit-to-lead studies to GLP toxicology.
- His experience includes managing IND-enabling studies, NDA-enabling non-clinical studies, clinical protocol development and site initiation, clinical biomarker development, CRO relationships, academic collaborations, and grant submissions.
- He has co-authored more than 30 peer-reviewed publications exploring binding target validation, in vitro/in vivo efficacy, therapeutic index, biomarker signatures and mechanism of action for cancer therapeutics targeting apoptosis pathways, tumor suppressor genes, cell surface receptors, stem cell self-renewal, NK cell activation as well as clinical biomarker studies in Phase I/II trials.
- He has presented his research work at international conferences and received various research and leadership awards.